Table 6. Recognition of HLA-binding proinsulin peptides
ELISpot responses in diabetic subjects*
Mean response in patients and controls
Peptides HLA Long-standing Recent-onset Total, % Patients Controls (n) P§
34–42 A2 2/4 4/10 43 10.2 ± 2.2 0.6 ± 0.3 (11) 0.003
38–46 A3 0/2 2/5 29 (2)
A11 1/1 1/2 67 (1)
39–48 A24 1/4 1/5 22 (2)
41–50 A1 3/7 4/4 64 32.2 ± 11.8 0.7 ± 0.4 (6) 0.02
A3 2/2 4/5 86 (2)
A11 0/1 1/2 33 (1)
42–51 A1 4/5 1/1 83 (2)
A2 2/4 6/7 73 26.9 ± 7.3 0.8 ± 0.5 (5) 0.02
B8 4/6 3/3 78 38.5 ± 15.4 2.1 ± 1.4 (4) 0.005
B18 1/1 3/4 80 (0)
44–51 A1 5/6 1/1 86 (2)
B8 5/6 2/3 78 32.7 ± 11.7 0 (4) 0.02
45–53 A3 1/2 2/4 50 (2)
49–57 B8 4/6 2/3 66 31.1 ± 13.1 0.3 ± 0.2 (4) 0.04
51–61 B8 0/7 2/6 15 5.6 ± 16.0 1.3 ± 0.9 (7) ns
  • * Number of responders/number of individuals tested

  • Mean ± SEM of stimulation score; n, number of controls

  • N- and C-terminal amino acids in proinsulin

  • § P value, nonparametric Mann–Whitney test; ns, nonsignificant